Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Medication Treatments

News
Indiana University Researchers to Study Use of Tezampanel for Opioid Withdrawal
10/05/2020
The Indiana University School of Medicine has received a $12.3 million grant from the National Institute on Drug Abuse for a two-stage research project to study the use of tezampanel to treat opioid withdrawal syndrome, as well as other...
The Indiana University School of Medicine has received a $12.3 million grant from the National Institute on Drug Abuse for a two-stage research project to study the use of tezampanel to treat opioid withdrawal syndrome, as well as other...
The Indiana University School of...
10/05/2020
Addiction Professional
News
FDA Seeks Public Input on Patient-Focused Drug Development for Stimulant Use Disorder
09/24/2020
The U.S. Food & Drug Administration announced that it will conduct a virtual public meeting on patient-focused drug development (PFDD) for stimulant use disorder, and the administration is seeking input from individuals and family members...
The U.S. Food & Drug Administration announced that it will conduct a virtual public meeting on patient-focused drug development (PFDD) for stimulant use disorder, and the administration is seeking input from individuals and family members...
The U.S. Food & Drug...
09/24/2020
Addiction Professional
News
MAT Pharmacy Program Expands to Arizona
09/02/2020
Cordant Health Solutions recently announced that it has expanded its addiction pharmacy program into Arizona with the opening of a pharmacy in Mesa. Cordant pharmacies work with clinicians in office-based opioid treatment (OBOT) programs who...
Cordant Health Solutions recently announced that it has expanded its addiction pharmacy program into Arizona with the opening of a pharmacy in Mesa. Cordant pharmacies work with clinicians in office-based opioid treatment (OBOT) programs who...
Cordant Health Solutions...
09/02/2020
Addiction Professional
News
Clinicians Prescribing Buprenorphine Far Below Limits of Waivers
08/28/2020
Research published on JAMA Network Open on Monday shows that about half of clinicians who are waivered to prescribe buprenorphine for the treatment of opioid use disorder have actually done so, and that a majority of clinicians are...
Research published on JAMA Network Open on Monday shows that about half of clinicians who are waivered to prescribe buprenorphine for the treatment of opioid use disorder have actually done so, and that a majority of clinicians are...
Research published on JAMA...
08/28/2020
Addiction Professional
News
Pregnant Women Shown to Face Additional Barriers to OUD Treatment in Study
08/19/2020
A study using trained actors attempting to get addiction treatment in 10 states found that pregnant women were about 20% less likely to be accepted for treatment vs. women who are not pregnant, with the largest discrepancy involving...
A study using trained actors attempting to get addiction treatment in 10 states found that pregnant women were about 20% less likely to be accepted for treatment vs. women who are not pregnant, with the largest discrepancy involving...
A study using trained actors...
08/19/2020
Addiction Professional
News
FDA Makes Series of Recommendations on Naloxone
08/18/2020
In an effort to reduce the risk of death from opioid overdose, the FDA recently made a series of recommendations around naloxone for both healthcare professionals and patients.
In an effort to reduce the risk of death from opioid overdose, the FDA recently made a series of recommendations around naloxone for both healthcare professionals and patients.
In an effort to reduce the risk...
08/18/2020
Addiction Professional
News
Study: 60% of Residential Programs Offer No MOUDs
08/04/2020
Medication-assisted treatment is referred to by many within the field as the “gold standard,” but a study published on JAMA Network Open in July shows that use of medications for opioid use disorder (MOUD) is anything but standard at...
Medication-assisted treatment is referred to by many within the field as the “gold standard,” but a study published on JAMA Network Open in July shows that use of medications for opioid use disorder (MOUD) is anything but standard at...
Medication-assisted treatment is...
08/04/2020
Addiction Professional
News
Study Assesses Two-Year Outcomes of OUD Patients Following Sublocade Clinical Trials
06/30/2020
In a study of long-term recovery in individuals with moderate to severe opioid use disorder following their transition from two Phase 3 clinical trials of Sublocade, the extended-release formulation of buprenorphine, 44% of participants...
In a study of long-term recovery in individuals with moderate to severe opioid use disorder following their transition from two Phase 3 clinical trials of Sublocade, the extended-release formulation of buprenorphine, 44% of participants...
In a study of long-term recovery...
06/30/2020
Addiction Professional
News
Temple Researchers Receive NIDA Grant to Study Cocaine Addiction Treatment
06/16/2020
Researchers at Temple University have received a $1.77 million grant from the National Institute on Drug Abuse to study the effects of a therapy for the treatment of cocaine use disorder, according to a report published by the Philly Voice.
Researchers at Temple University have received a $1.77 million grant from the National Institute on Drug Abuse to study the effects of a therapy for the treatment of cocaine use disorder, according to a report published by the Philly Voice.
Researchers at Temple University...
06/16/2020
Addiction Professional
News
NCAD Spotlight: Assessing Advancements in OUD Medications and Their Delivery
06/10/2020
Progress continues on the development of new formulations of medicines to treat opioid use disorder. One extended release formulation of buprenorphine, Sublocade, was approved for use in the U.S. in 2018, and another, Brixadi, could get final...
Progress continues on the development of new formulations of medicines to treat opioid use disorder. One extended release formulation of buprenorphine, Sublocade, was approved for use in the U.S. in 2018, and another, Brixadi, could get final...
Progress continues on the...
06/10/2020
Addiction Professional

Advertisement

Advertisement

Browse Our Other Brands

Psych NP Institute

 

Psych Congress Network

 

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement